Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Genitourinary 1

Conditions

Sexuality 1Sexual Dysfunction, Physiological 1Radiation Injuries 1Prostatic Neoplasms 1Erectile Dysfunction 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × ArginMax × Clear all
NCT00459134 2021-09-28

L-Arginine Supplements in Treating Women Who Are Cancer Survivors

Wake Forest University Health Sciences

Phase NA Completed
186 enrolled 11 charts
Other

Sexual Dysfunction, Physiological, Sexuality

NCT01105130 2021-09-28

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

Wake Forest University Health Sciences

Phase 2 Completed
140 enrolled 13 charts
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡